AUSTRALIA'S ‘research engine' SLOWS DOWN
BioSpectrum Asia|June 2020
As the COVID-19 has spread around the globe, it has created profound disruption across communities, patients and clinicians. Pharma and medtech companieshave found themselves front and center—supplying (and rapidly scaling up) vitally important medical products to support patients in their time of need, while also attracting widespread attention as the industry sprints to develop new therapeutics and vaccines for COVID-19. At the same time, the clinical and product development “research engine” has experienced profound disruption as colleagues adjust to remote work environments and lab capacity is reduced. Due to this crisis the focus has been now devoted to COVID-19 affecting research and development in other areas across the globe including R&D in Australia.
Narayan Kulkarni
AUSTRALIA'S ‘research engine' SLOWS DOWN

What impact is the pandemic having and likely to have on Australia’s research workforce and will we have the research workforce capability to support our recovery efforts? Responding to this question from the Australia’s Industry, Science and Technology Minister, Karen Andrews; Health Minister, Greg Hunt; and Education Minister, Dan Tehan, Australia’s Chief Scientist, Dr Alan Finkel haveconvenedRapid Research Information Forum (RRIF), a group of 35 research sector lead organizations,and its operations are led by the Australian Academy of Science. The RRIF has come up with report titled “Impact of the Pandemic on Australia’s Research Workforce”. The report noted that the Australian medical research workforce will be severely impacted for an extended period of time.

The report was submitted on May 6, to Neville Power, Chair and David Thodey, Deputy Chair, National COVID-19 Co-ordination Commission (NCCC), a strategic advisory body for the national response to the COVID-19 pandemic by the Australian Government. The NCCC was established on March 25, 2020 by Prime Minister Scott Morrison to provide advice on public–private partnerships and coordination to mitigate the social and economic impacts of the COVID-19 pandemic in Australia.

Bu hikaye BioSpectrum Asia dergisinin June 2020 sayısından alınmıştır.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

Bu hikaye BioSpectrum Asia dergisinin June 2020 sayısından alınmıştır.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

BIOSPECTRUM ASIA DERGISINDEN DAHA FAZLA HIKAYETümünü görüntüle
Korea develops micro-structured artificial lung model using bioprinting technology
BioSpectrum Asia

Korea develops micro-structured artificial lung model using bioprinting technology

A team of Korean researchers has made a breakthrough that will greatly enhance the efficiency of respiratory disease research, garnering attention.

time-read
1 min  |
BioSpectrum Asia Sep 2024
Philips names Ling Liu as Chief Region Leader of Greater China
BioSpectrum Asia

Philips names Ling Liu as Chief Region Leader of Greater China

Royal Philips, a global leader in health technology, has announced the appointment of Ling Liu as the Chief Region Leader of Philips Greater China.

time-read
1 min  |
BioSpectrum Asia Sep 2024
PW Skills launches School of Healthcare to solve India's critical shortage of medical professionals
BioSpectrum Asia

PW Skills launches School of Healthcare to solve India's critical shortage of medical professionals

PW Skills, the upskilling vertical of Physics Wallah (PW) has announced the launch of School of Healthcare across five cities in India, namely, Noida, Indore, Lucknow, Patna and Delhi.

time-read
1 min  |
BioSpectrum Asia Sep 2024
Australian biotech incubator Proto Axiom announces $20 M Series B first close
BioSpectrum Asia

Australian biotech incubator Proto Axiom announces $20 M Series B first close

Proto Axiom, the Australian biomedical technology incubator, has announced a $20 million first close of its targeted $30 million Series B, to bolster Australia's biotechnology sector through increased intellectual property (IP) retention.

time-read
1 min  |
BioSpectrum Asia Sep 2024
Biogen, Beckman Coulter and Fujirebio to develop new tests for tau pathology
BioSpectrum Asia

Biogen, Beckman Coulter and Fujirebio to develop new tests for tau pathology

Biogen Inc., Beckman Coulter, Inc. (both based in the US) and Japan-based Fujirebio have announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialise new tests for tau pathology in Alzheimer’s disease (AD).

time-read
1 min  |
BioSpectrum Asia Sep 2024
Pfizer upgrades pharma production plant in Melbourne
BioSpectrum Asia

Pfizer upgrades pharma production plant in Melbourne

Australia is stepping up to the global fight against antimicrobial resistance, as Pfizer Australia announces a major upgrade to its manufacturing facility in Melbourne, Victoria.

time-read
1 min  |
BioSpectrum Asia Sep 2024
mRNA as novel active ingredient - Plasmid Factory providing the template for tomorrow's vaccines
BioSpectrum Asia

mRNA as novel active ingredient - Plasmid Factory providing the template for tomorrow's vaccines

PlasmidFactory GmbH was founded in 2000 in Bielefeld/Germany with 4 employees. In the meantime, under the founder and managing director Dr. Martin Schleef, the company has become a well-known contract manufacturer (CDMO) for plasmid and minicircle DNA. Today, PlasmidFactory has ~50 highly qualified employees, and has established a GMP manufacturing facility.

time-read
6 dak  |
BioSpectrum Asia Sep 2024
"Our priorities will include identifying and understanding the challenges while engaging regularly with industry leaders to address their concerns"
BioSpectrum Asia

"Our priorities will include identifying and understanding the challenges while engaging regularly with industry leaders to address their concerns"

K Raja Bhanu has been elevated from Executive Director to Director General of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), effective July 1, 2024. Bhanu brings a wealth of experience from his distinguished career in drug control and regulation. He has a proven track record in advancing drug quality, safety, and regulatory compliance. His leadership at the Drug Control Administration (DCA) was marked by significant initiatives that enhanced drug regulation standards and reinforced India's pharmaceutical reputation globally. In his current role, Bhanu is set to drive the expansion of India's pharmaceutical exports, boost global competitiveness, and adeptly navigate the complexities of international regulations, leveraging his extensive expertise to foster industry growth and global prominence. In an interaction with BioSpectrum, he shared his plans on addressing many challenges before the Indian pharma industry to stay compliant with international regulations. Edited excerpts:

time-read
4 dak  |
BioSpectrum Asia Sep 2024
"Australia has long been a global leader in research, yet our biotech sector has not lived up to its full potential"
BioSpectrum Asia

"Australia has long been a global leader in research, yet our biotech sector has not lived up to its full potential"

Australia's first true biotech incubator, Proto Axiom, has secured $20 million in the first close of its $30 million Series B round to strengthen the nation's biotech sector through greater IP retention. Anthony Liveris, CEO of Proto Axio discusses the incubator's selection criteria, identifying the most promising biotech trends for global health, and outlining the key strengths that make Australian biotech globally competitive. Edited excerpts:

time-read
2 dak  |
BioSpectrum Asia Sep 2024
Unleashing Innovative Wound Care Solutions
BioSpectrum Asia

Unleashing Innovative Wound Care Solutions

The incidence of wounds is rising, especially in the Asia-Pacific (APAC) region. In Australia alone, 420,000 individuals are impacted by chronic wounds, leading to direct healthcare costs of AUD $3 billion, representing 2 per cent of the country's total healthcare expenditure. Similarly, data from Singapore between 2000 and 2017 revealed that the incidence of wounds among hospitalised adults was 300 per 100,000 for those over 18 and 800 per 100,000 for those over 50. Let's explore further.

time-read
5 dak  |
BioSpectrum Asia Sep 2024